In this episode of LATAM MedTech Insights, we dissect the sudden and impactful new regulation from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). International manufacturers are now facing unprecedented requirements for localized clinical data and stringent cybersecurity protocols, effectively rewriting the rulebook for market access in Latin America's largest economy.

We explore the immediate consequences of this regulatory shift, moving beyond the headlines to analyze the strategic and financial implications. We discuss why existing clinical data from bodies like the FDA or the EU may no longer be sufficient for ANVISA and what this means for your product launch timeline. This episode provides the critical insights you need to understand and navigate this challenging new environment.

**Key Takeaways This Episode:**

* How does Brazil's new rule redefine the clinical data requirements for AI-driven SaMD?

* What are the specific cybersecurity mandates that international manufacturers are most likely to overlook?

* Why might your existing technical dossier be immediately rejected under this new framework?

* What is the single biggest mistake companies make when adapting their global strategy for Brazil's new regulations?

* Are there new local data residency requirements you haven't considered for your cloud-based platform?

* How can you turn this new regulatory hurdle into a competitive advantage?

Navigating sudden regulatory shifts is a core challenge for global MedTech companies. At Pure Global, we offer end-to-end regulatory consulting solutions, combining deep local expertise in markets like Brazil with advanced AI and data tools to streamline your market access. From developing a new clinical strategy to ensuring your cybersecurity plan meets ANVISA's strict standards, we act as your local partner to turn regulatory complexity into a clear pathway to success. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help.